Form 4: Royalty Pharma Director Bonnie L. Bassler Acquires Shares in Lieu of Retainer

Director Bonnie L. Bassler acquired 1,141 Class A Ordinary Shares of Royalty Pharma plc in lieu of a quarterly retainer payment.

Summary

• On March 31, 2025, Bonnie L. Bassler, a director of Royalty Pharma plc, acquired 1,141 Class A Ordinary Shares.
• The shares were issued under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The acquisition was in lieu of a quarterly retainer payment of $37,500, with the shares acquired at a price of $32.8658 each.
• Following the transaction, Ms. Bassler beneficially owns 62,440 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, indicating confidence in the company's future. The transaction is part of a pre-existing compensation plan, so it's not a surprise, but still a positive signal.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of the equity incentive plan aligns director compensation with shareholder interests.

Industry Context

Director share acquisitions are common and often viewed positively, as they align the interests of directors with those of shareholders. Equity incentive plans are a standard method of compensating directors and employees in publicly traded companies.

Comparison to Industry Standards

• Director compensation through equity is a common practice among publicly listed companies.
• The specific amount and structure of equity compensation vary based on company size, industry, and individual director roles.
• Comparing Royalty Pharma's director compensation plan to those of similar pharmaceutical or investment companies would provide a more detailed benchmark.

Stakeholder Impact

• Shareholders may view the director's share acquisition positively, as it aligns interests.
• The transaction has a minimal direct impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Royalty Pharma, Director, Share Acquisition, Equity Incentive Plan, Form 4, RPRX, Beneficial Ownership